Company profile PHVS
After 39 days of this quarter the interest is at 41.0. Based on that we can calculate that during remaining 52 days it will total up to 96.0. Pharvaris expected interest is significantly lower compared to previous quarter (-60.0%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 92 | 94 2.2% QoQ | 59 -37.2% QoQ | 107 81.4% QoQ |
| 2020 | 26 -71.7% YoY -75.7% QoQ | 112 19.1% YoY 330.8% QoQ | 116 96.6% YoY 3.6% QoQ | 177 65.4% YoY 52.6% QoQ |
| 2021 | 125 380.8% YoY -29.4% QoQ | 87 -22.3% YoY -30.4% QoQ | 66 -43.1% YoY -24.1% QoQ | 109 -38.4% YoY 65.2% QoQ |
| 2022 | 60 -52.0% YoY -45.0% QoQ | 116 33.3% YoY 93.3% QoQ | 252 281.8% YoY 117.2% QoQ | 202 85.3% YoY -19.8% QoQ |
| 2023 | 91 51.7% YoY -55.0% QoQ | 137 18.1% YoY 50.5% QoQ | 124 -50.8% YoY -9.5% QoQ | 240 18.8% YoY 93.5% QoQ |
| 2024 | 41 -54.9% YoY -82.9% QoQ | - | - | - |
The average 5 years interest of Pharvaris was 9.32 per week. The last year interest of Pharvaris compared to the last 5 years has changed by 24.25%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 64.02%.
There is not enough data for PHA121 to provide analysis
There is not enough data for PHA121 to provide correlation calculation
There is not enough data for PHA121 to provide analysis
After 39 days of this quarter the interest is at 129.0. Based on that we can calculate that during remaining 52 days it will total up to 301.0. hereditary angioedema treatment expected interest is significantly higher compared to previous quarter (+356.1%) and same quarter last year (+258.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 23 | 33 43.5% QoQ | 100 203.0% QoQ | 60 -40.0% QoQ |
| 2020 | 32 39.1% YoY -46.7% QoQ | 43 30.3% YoY 34.4% QoQ | 54 -46.0% YoY 25.6% QoQ | 57 -5.0% YoY 5.6% QoQ |
| 2021 | 111 246.9% YoY 94.7% QoQ | 82 90.7% YoY -26.1% QoQ | 56 3.7% YoY -31.7% QoQ | 73 28.1% YoY 30.4% QoQ |
| 2022 | 61 -45.0% YoY -16.4% QoQ | 35 -57.3% YoY -42.6% QoQ | 98 75.0% YoY 180.0% QoQ | 81 11.0% YoY -17.3% QoQ |
| 2023 | 84 37.7% YoY 3.7% QoQ | 57 62.9% YoY -32.1% QoQ | 20 -79.6% YoY -64.9% QoQ | 66 -18.5% YoY 230.0% QoQ |
| 2024 | 129 53.6% YoY 95.5% QoQ | - | - | - |
The average 5 years interest of hereditary angioedema treatment was 5.19 per week. The last year interest of hereditary angioedema treatment compared to the last 5 years has changed by 22.93%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 39.91%.
There is not enough data for PHVS416 clinical trial to provide analysis
There is not enough data for PHVS416 clinical trial to provide correlation calculation
There is not enough data for PHVS416 clinical trial to provide analysis
There is not enough data for acute HAE attacks treatment to provide analysis
There is not enough data for acute HAE attacks treatment to provide correlation calculation
There is not enough data for acute HAE attacks treatment to provide analysis
There is not enough data for PHVS719 clinical trial to provide analysis
There is not enough data for PHVS719 clinical trial to provide correlation calculation
There is not enough data for PHVS719 clinical trial to provide analysis
There is not enough data for HAE prophylactic tablet to provide analysis
There is not enough data for HAE prophylactic tablet to provide correlation calculation
There is not enough data for HAE prophylactic tablet to provide analysis
There is not enough data for rare disease therapies to provide analysis
There is not enough data for rare disease therapies to provide correlation calculation
There is not enough data for rare disease therapies to provide analysis
There is not enough data for Pharvaris stock price to provide analysis
There is not enough data for Pharvaris stock price to provide correlation calculation
There is not enough data for Pharvaris stock price to provide analysis
There is not enough data for Pharma company in the Netherlands to provide analysis
There is not enough data for Pharma company in the Netherlands to provide correlation calculation
There is not enough data for Pharma company in the Netherlands to provide analysis